She noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

If you purchased or acquired securities in ESSA Pharma between December 12, 2023 and October 31, 2024 and would like to ...

The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...

Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient ...

Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...

Adding talazoparib to first-line treatment with enzalutamide can improve overall survival in patients with mCRPC, phase 3 data suggest.

Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...

NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

According to the lawsuit, defendants, throughout the Class Period, failed to disclose to investors that: (1) masofaniten in combination with enzalutamide had no clear efficacy benefit over ...